ICICI 3-in-1 Account Login

KOPRAN SHARE PRICE

Sector Pharmaceuticals
BSE 524280
NSE KOPRAN
182.31
-4.36 (-2.34 %)
Buy
B
Sell
S
NSE BSE

Overview

Day Low

179.93

Day High

185.00

52 Week Low

155.00

52 Week High

369.70

All Time Low

6.00

All Time High

370.45

Open

184.89

Close

186.67

Volume

332,745

Mkt cap (Cr)

880.30

P/E ratio

22.87

P/B ratio

0.59%

Div yield

1.64%

6M return

-19.26%

1Y return

-27.06%

1D 1W 1M 3M 6M 1Yr 3Yr 5Yr 10Yr Max
Price PE Ratio
 

We appreciate your patience. Your content is on the way.

SWOT Analysis

  • S
  • W
  • O
  • T

Technical Analysis

Moving Averages

EMA SMA
 

We appreciate your patience. Your content is on the way.

182.31 -2.34%

Current Price

  • Bullish Moving Averages
  • Bearish Moving Averages

Resistance and support

 

We appreciate your patience. Your content is on the way.

Company Financials

  • Profit and loss statement
  • Balance sheet
  • Quarterly Result
  • Ratio
 

We appreciate your patience. Your content is on the way.

Quick Results Snapshot

 

We appreciate your patience. Your content is on the way.

Shareholding Pattern

Summary

 

We appreciate your patience. Your content is on the way.

 

We appreciate your patience. Your content is on the way.

Historical Promoter Summary

 

We appreciate your patience. Your content is on the way.

Promoter Holding(%)

Historical FII Holdings

 

We appreciate your patience. Your content is on the way.

FII Holding(%)

Historical MF Holdings

 

We appreciate your patience. Your content is on the way.

MF Holding(%)

Stocks Comparison
Table Chart

 

We appreciate your patience. Your content is on the way.

Corporate Action

  • Announcement
  • Board Meeting
  • Dividend
  • Split
  • Rights
  • Events

Insider & Institutional Activity

  • Bulk Block Deals
  • Insider Trading & SAST
 

We appreciate your patience. Your content is on the way.

About Kopran Ltd

Stock PE (TTM)

22.87

Promoter Holding

44.42%

Book Value

107.3499

ROCE

13.57%

ROE

10.95%

Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.`92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the world`s highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran`s bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran`s high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce. The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda. The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002. The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres. The company has also increased its installed capacity of Tablets & Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos). In Feb. 2001, Kopran tied up with E-Merck for co-marketing a new anti-inflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fast-moving non-steroid anti-inflammatory drugs (NSAID),has been launched in the international market. The Company also launched Cholestat (Atorvastatin - a cholesterol reducer) and further gave co-marketing rights for Atorvastatin to E-Merck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004. Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007. The Company during the FY 2014-15 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015.

Kopran share price as on 18 May 2025 is Rs. 182.31. Over the past 6 months, the Kopran share price has decreased by 19.26% and in the last one year, it has decreased by 27.06%. The 52-week low for Kopran share price was Rs. 155 and 52-week high was Rs. 369.7.

Read More
Registered Office  
Registrars  
Management  
Listing Info  

524280

KOPRAN

INE082A01010

Sep

Kopran Ltd FAQs

You can buy Kopran Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Kopran Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 16, 2025 03:54 PM the closing price of Kopran Ltd was Rs.182.31.

The latest PE ratio of Kopran Ltd as of May 16, 2025 03:54 PM is 22.87

The latest PB ratio of Kopran Ltd as of May 16, 2025 03:54 PM is 0.59

The 52-week high of Kopran Ltd share price is Rs. 369.70 while the 52-week low is Rs. 155.00

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of May 16, 2025 03:54 PM, the market cap of Kopran Ltd stood at Rs. 880.30 Cr.

Market Outlook

View all
 

We appreciate your patience. Your content is on the way.